The JAK3 and STAT5 inhibitors were used to validate the involvement of JAK3/STAT5 pathway in enhancing the role of cisplatin sensitivity of NSCLC cells by IL‐7. The gene discussed is JAK3; the disease is non-small cell lung carcinoma.